UPDATE: European Regulator Suspends Glaxo's Diabetes Drugs - WSJ.com: "The European Medicines Agency Thursday suspended marketing authorization for GlaxoSmithKline PLC's (GSK) controversial diabetes drug rosiglitazone because fresh data show the risks of taking the drug outweigh its benefits, and it said the medicines containing it will stop being available in Europe within the next few months.
The EMA -- the decentralized European body responsible for licensing rosiglitazone in 2000 and which held an extraordinary expert meeting earlier this month to review the drug's safety"
The EMA -- the decentralized European body responsible for licensing rosiglitazone in 2000 and which held an extraordinary expert meeting earlier this month to review the drug's safety"
